Neurotez, Inc. to Present at the 10^th Annual BIO CEO & Investor Conference

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Neurotez, Inc., a company developing therapies for Alzheimer’s disease, today announced that Chief Executive Officer Dr. Nikolaos Tezapsidis will present an overview of the Company at the 10^th Annual BIO CEO & Investor Conference in New York on Wednesday, February 13, 2008, 11:45am at the Park Avenue Suite of The Waldorf Astoria Hotel.

About Neurotez, Inc.

Neurotez, Inc. a private development-stage corporation proposes to undertake the clinical development of leptin to further its commercialization as a therapy for Alzheimer’s disease (AD) by leveraging existing data from preclinical and animal studies along with extensive clinical data to proceed with an IND filing. Additional products in the discovery stage are targeting familial AD. AD is the primary cause of cognitive impairment among the elderly. It is estimated that up to 50% of 85 year olds may have AD and there are currently 5 million with AD in the US alone. For more information, please visit www.neurotez.com.